Puglisi C V, Meyer J C, D'Arconte L, Brooks A, de Silva J A
J Chromatogr. 1978 Jan 1;145(1):81-96. doi: 10.1016/s0378-4347(00)81670-9.
A sensitive and specific electron-capture gas--liquid chromatographic (GLC--ECD) assay was developed for the determination of 8-chloro-6-(2'-fluorophenyl)-1-methyl-4H-imidazo(1,5a)(1,4)benzodiazepine (I) or 8-chloro-1,4-dimethyl-6-(2'-fluorophenyl)-4H-imidazo (1,5a)(1,4)benzodiazepine (II) in blood. The assay for both compounds involves extraction into benzene--methylene chloride (9:1) from blood buffered to pH 12.6 The overall recovery of I and II from blood is 86% +- 5.0 (S.D.) and the sensitivity limit of detection is of the order of 2 to 3 ng of I or II per milliltre of blood. The major urinary metabolite of I is 8-chloro-6-(2'-fluorophenyl)-1-hydroxymethyl-4H-imidazo(1,5a)(1,4)benzodiazepine, (IA) present as a glucuronide conjugate while 8-chloro-6-(2'-fluorophenyl)-4-hydroxyl-1-methyl-4H-imidazo(1,5a)(1,4)benzodiazepine, (IB) and 8-chloro-6-(2'-fluorophenyl)-4-hydroxy-1-hydroxymethyl-4H-imidazo(1,5a)(1,4) benzodiazepine, (IC) are minor metabolites. The major metabolite IA is extracted into benzene--methylene chloride (9:1) from urine buffered to pH 11.0 (after incubation with glucuronidase--sulfatase as pH 5.0), and analyzed by differential pulse polarography (DPP) in 0.1 M phosphate buffer PH 3). The overall recovery of IA is 84 +- 3.0% (S.D.) with a sensitivity limit of 50 ng per millilitre of urine. The metabolites of compound II have not as yet been elucidated. The GLC--ECD and DPP assays were applied to the determination of blood levels and urinary excretion in dogs following single 10 mg/kg intravenous and oral doses of I and following single 6 mg/kg intravenous and 10 mg/kg oral doses of II. Blood levels of compound I were also evaluated in man following intravenous infusion of single 10 mg doses.
已开发出一种灵敏且特异的电子捕获气-液色谱法(GLC-ECD),用于测定血液中的8-氯-6-(2'-氟苯基)-1-甲基-4H-咪唑并(1,5a)(1,4)苯二氮䓬(I)或8-氯-1,4-二甲基-6-(2'-氟苯基)-4H-咪唑并(1,5a)(1,4)苯二氮䓬(II)。两种化合物的测定方法均包括从pH调至12.6的血液中萃取到苯-二氯甲烷(9:1)中。I和II从血液中的总回收率为86%±5.0(标准差),检测灵敏度极限约为每毫升血液中2至3纳克的I或II。I的主要尿代谢物是8-氯-6-(2'-氟苯基)-1-羟甲基-4H-咪唑并(1,5a)(1,4)苯二氮䓬(IA),以葡萄糖醛酸苷共轭物形式存在,而8-氯-6-(2'-氟苯基)-4-羟基-1-甲基-4H-咪唑并(1,5a)(1,4)苯二氮䓬(IB)和8-氯-6-(2'-氟苯基)-4-羟基-1-羟甲基-4H-咪唑并(1,5a)(1,4)苯二氮䓬(IC)是次要代谢物。主要代谢物IA从pH调至11.0的尿液中(在pH 5.0与葡萄糖醛酸酶-硫酸酯酶孵育后)萃取到苯-二氯甲烷(9:1)中,并在0.1 M磷酸盐缓冲液pH 3)中通过差分脉冲极谱法(DPP)进行分析。IA的总回收率为84±3.0%(标准差),灵敏度极限为每毫升尿液50纳克。化合物II的代谢物尚未阐明。GLC-ECD和DPP测定法用于测定犬单次静脉注射和口服10毫克/千克剂量的I以及单次静脉注射6毫克/千克和口服10毫克/千克剂量的II后的血药浓度和尿排泄情况。还对人静脉输注单次10毫克剂量的I后的血药浓度进行了评估。